182 related articles for article (PubMed ID: 35705329)
1. Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations.
Li Y; Zhang P; An Z; Yue C; Wang Y; Liu Y; Yuan X; Ma Y; Li K; Yin Z; Wang L; Wang H
Respirology; 2022 Oct; 27(10):844-853. PubMed ID: 35705329
[TBL] [Abstract][Full Text] [Related]
2. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.
Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y
Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356
[TBL] [Abstract][Full Text] [Related]
3. [Effect of influenza and 23-valent pneumococcal polysaccharide vaccinations on elderly with chronic obstructive pulmonary diseases: a community-based intervention study].
Wen Y; He L; Zhai Y; Wu J; Chen YY; Wang H; Zong QQ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Jun; 39(6):792-798. PubMed ID: 29936749
[No Abstract] [Full Text] [Related]
4. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
5. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.
Walters JA; Tang JN; Poole P; Wood-Baker R
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD001390. PubMed ID: 28116747
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.
Chiou WY; Lee MS; Hung SK; Lin HY; Lo YC; Hsu FC; Tsai SJ; Li CY
BMJ Open; 2018 May; 8(5):e019364. PubMed ID: 29769253
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
[TBL] [Abstract][Full Text] [Related]
8. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1).
Chan TC; Hung IF; Luk JK; Shea YF; Chan FH; Woo PC; Chu LW
J Am Med Dir Assoc; 2012 Oct; 13(8):698-703. PubMed ID: 22722051
[TBL] [Abstract][Full Text] [Related]
9. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
[TBL] [Abstract][Full Text] [Related]
10. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events.
Ihara H; Kikuchi K; Taniguchi H; Fujita S; Tsuruta Y; Kato M; Mitsuishi Y; Tajima K; Kodama Y; Takahashi F; Takahashi K; Azuma N
Vaccine; 2019 Oct; 37(43):6447-6453. PubMed ID: 31526624
[TBL] [Abstract][Full Text] [Related]
11. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.
Dransfield MT; Harnden S; Burton RL; Albert RK; Bailey WC; Casaburi R; Connett J; Cooper JA; Criner GJ; Curtis JL; Han MK; Make B; Marchetti N; Martinez FJ; McEvoy C; Nahm MH; Niewoehner DE; Porszasz J; Reilly J; Scanlon PD; Scharf SM; Sciurba FC; Washko GR; Woodruff PG; Lazarus SC;
Clin Infect Dis; 2012 Sep; 55(5):e35-44. PubMed ID: 22652582
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.
Domínguez A; Castilla J; Godoy P; Delgado-Rodríguez M; Saez M; Soldevila N; Astray J; Mayoral JM; Martín V; Quintana JM; González-Candelas F; Galán JC; Tamames S; Castro A; Baricot M; Garín O; Pumarola T;
Hum Vaccin Immunother; 2013 Apr; 9(4):865-73. PubMed ID: 23563516
[TBL] [Abstract][Full Text] [Related]
13. Influenza and pneumococcal vaccination coverage and associated factors in patients hospitalized with acute exacerbations of COPD in China: Findings from real-world data.
He R; Ren X; Huang K; Lei J; Niu H; Li W; Dong F; Li B; Wang Y; Yang T; Wang C
Chin Med J (Engl); 2024 May; 137(10):1179-1189. PubMed ID: 37488669
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
[TBL] [Abstract][Full Text] [Related]
15. Real-World Coverage With Influenza, Pneumococcal, and Herpes Zoster Vaccines Among Patients With Rheumatic Diseases in a Nationwide Healthcare Plan.
Furer V; Weil C; Chodik G; Slav SA; Blonder SN; Fisher-Shoval Y; Barak M; Elkayam O
J Rheumatol; 2024 May; 51(5):505-516. PubMed ID: 38302167
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain.
Domínguez À; Soldevila N; Toledo D; Torner N; Force L; Pérez MJ; Martín V; Rodríguez-Rojas L; Astray J; Egurrola M; Sanz F; Castilla J;
PLoS One; 2017; 12(2):e0171943. PubMed ID: 28187206
[TBL] [Abstract][Full Text] [Related]
18. Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness.
Sanei F; Wilkinson T
Ther Adv Respir Dis; 2016 Aug; 10(4):349-67. PubMed ID: 27193567
[TBL] [Abstract][Full Text] [Related]
19. Should Patients With COPD Be Vaccinated?
Cimen P; Unlu M; Kirakli C; Katgi N; Ucsular FD; Ayranci A; Guclu SZ
Respir Care; 2015 Feb; 60(2):239-43. PubMed ID: 25316894
[TBL] [Abstract][Full Text] [Related]
20. Response to Shami et al. 'Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single dose vaccination strategy for adults in Hong Kong' (Hum Vacc Immunother 2020).
Buchwald UK; Folaranmi T; Weiss T
Hum Vaccin Immunother; 2021 Jan; 17(1):173-175. PubMed ID: 32614654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
